These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27487675)

  • 1. [Cardiovascular safety of antidiabetics].
    Aline Roth PW; Jornayvaz FR
    Rev Med Suisse; 2016 Jun; 12(521):1084, 1086-8. PubMed ID: 27487675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
    Scheen AJ
    Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
    Scheen AJ; Piérard L; Krzesinski JM; Paquot N
    Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
    Ametov AS; P'ianykh OP; Chernikova NA
    Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.
    Scheen AJ
    Diabetes Metab; 2016 Apr; 42(2):71-6. PubMed ID: 26856453
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral Antidiabetic Agents and Cardiovascular Outcomes.
    Pareek M; Bhatt DL
    Curr Probl Cardiol; 2018 Mar; 43(3):111-126. PubMed ID: 28844525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial.
    Alzaid A
    Diabetes Technol Ther; 2017 Jun; 19(6):324-327. PubMed ID: 28300428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits.
    Madievsky R
    Perm J; 2018; 22():18-034. PubMed ID: 30227909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cardiovascular Effects of Antidiabetic Therapies].
    Laubner K; Seufert J
    Dtsch Med Wochenschr; 2017 May; 142(10):737-745. PubMed ID: 28514822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does intensive glycemic control improve cardiovascular outcomes?
    Pendergrass M
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
    [No Abstract]   [Full Text] [Related]  

  • 14. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):429-442. PubMed ID: 28121469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 16. [New antidiabetic medications: at the dawn of a revolution? New therapeutic options for type 2 diabetes are challenged for cardiovascular disease prevention].
    Crenier L
    Rev Med Brux; 2016; 37(4):349-355. PubMed ID: 28525236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current perspectives on cardiovascular outcome trials in diabetes.
    Schnell O; Rydén L; Standl E; Ceriello A;
    Cardiovasc Diabetol; 2016 Oct; 15(1):139. PubMed ID: 27716274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?
    John M; Gopalakrishnan Unnikrishnan A; Kalra S; Nair T
    Indian Heart J; 2016; 68(4):564-71. PubMed ID: 27543483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.